Adma Biologics Inc (NASDAQ: ADMA) is 13.12% higher on its value in year-to-date trading and has touched a low of $5.91 and a high of $23.64 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $18.68 in the last trading session, with the day’s gains setting it 0.72%.
Currently trading at $19.40, the stock is -0.23% and 9.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.05 million and changing 3.85% at the moment leaves the stock 12.77% off its SMA200. ADMA registered 221.19% gain for a year compared to 6-month loss of -4.55%. The firm has a 50-day simple moving average (SMA 50) of $17.7052 and a 200-day simple moving average (SMA200) of $17.203625.
The stock witnessed a 8.32% gain in the last 1 month and extending the period to 3 months gives it a 4.53%, and is 7.72% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.52% over the week and 6.55% over the month.
Adma Biologics Inc (ADMA) has around 685 employees, a market worth around $4.61B and $426.45M in sales. Current P/E ratio is 23.97 and Fwd P/E is 19.66. Profit margin for the company is 46.35%. Distance from 52-week low is 228.26% and -17.94% from its 52-week high. The company has generated returns on investments over the last 12 months (45.98%).
with sales reaching $116.4M over the same period.The EPS is expected to grow by 45.61% this year, but quarterly earnings will post 16.13% year-over-year. Quarterly sales are estimated to grow 42.17% in year-over-year returns.
Adma Biologics Inc (ADMA) Top Institutional Holders
441.0 institutions hold shares in Adma Biologics Inc (ADMA), with institutional investors hold 90.74% of the company’s shares. The shares outstanding are 236.62M, and float is at 229.31M with Short Float at 5.65%. Institutions hold 88.38% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.0221% of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.3426 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.6668% and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8401 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Grossman Adam S, the company’s President and CEO. SEC filings show that Grossman Adam S sold 21,000 shares of the company’s common stock on Mar 19 ’25 at a price of $18.92 per share for a total of $0.4 million. Following the sale, the insider now owns 2.06 million shares.
Still, SEC filings show that on Nov 22 ’24, Tade Brad L. (CFO and Treasurer) disposed off 15,000 shares at an average price of $21.15 for $0.32 million. The insider now directly holds 199,433 shares of Adma Biologics Inc (ADMA).
